Drugs in MeSH Category Sclerosing Solutions

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	SODIUM TETRADECYL SULFATE	sodium tetradecyl sulfate	INJECTABLE;INJECTION	209937-001	Dec 9, 2019	AP	RX	No	No
Mylan Institutional	SOTRADECOL	sodium tetradecyl sulfate	INJECTABLE;INJECTION	040541-001	Nov 12, 2004		RX	No	Yes
Elkins Sinn	SOTRADECOL	sodium tetradecyl sulfate	INJECTABLE;INJECTION	005970-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Mylan Institutional	SOTRADECOL	sodium tetradecyl sulfate	INJECTABLE;INJECTION	040541-002	Nov 12, 2004	AP	RX	No	Yes
Elkins Sinn	SOTRADECOL	sodium tetradecyl sulfate	INJECTABLE;INJECTION	005970-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Sclerosing Solutions Market Dynamics and Patent Landscape

Last updated: July 31, 2026

Sclerosing solutions are injectable agents used to obliterate blood vessels, primarily for varicose veins, telangiectasias, hemorrhoids, lymphatic malformations, and selected vascular malformations. The NLM MeSH class includes chemical sclerosants such as polidocanol, sodium tetradecyl sulfate, ethanolamine oleate, sodium morrhuate, and hypertonic saline. The commercial market is mature, fragmented, and largely generic. Patent risk is concentrated in foam delivery systems, catheter-based administration, manufacturing processes, and combination or image-guided procedures rather than in the core liquid active ingredients.

What drugs are included in the NLM MeSH class Sclerosing Solutions?

The MeSH category covers agents that produce endothelial injury, thrombosis, and subsequent fibrosis after injection. The principal commercial substances are:

Sclerosing agent	Common dosage forms	Primary use	U.S. regulatory position
Polidocanol	Liquid injection; physician-compounded or proprietary foam	Spider veins, reticular veins, varicose veins	FDA-approved as Asclera; FDA-approved as Varithena foam
Sodium tetradecyl sulfate	Injectable solution	Varicose veins and spider veins	FDA-approved as Sotradecol
Ethanolamine oleate	Injectable solution	Esophageal varices and hemorrhoidal indications in certain markets	Historically marketed in the U.S.; regulatory status depends on product and indication
Sodium morrhuate	Injectable solution	Varicose veins and vascular lesions	Legacy product with limited current commercial presence
Hypertonic saline	Injectable solution	Varicose veins and selected vascular lesions	Often compounded or used under practice-specific protocols
Absolute ethanol	Injectable solution	Vascular malformations and specialized interventional procedures	Primarily procedure-based and institution-controlled use

The MeSH classification is pharmacologic, not a list of currently marketed products. Inclusion in the class does not establish FDA approval, current commercial availability, or Orange Book listing.

How large is the sclerosing solutions market?

The market is divided between routine phlebology procedures and hospital-based treatment of complex vascular lesions. Liquid sclerosants remain price-sensitive products, while proprietary foam and procedure systems command higher margins.

Market segments

Segment	Main products	Buyer base	Commercial characteristics
Cosmetic vein treatment	Polidocanol, sodium tetradecyl sulfate	Vein clinics, dermatologists, cosmetic practices	High procedure volume; low drug cost relative to physician fees
Medical varicose-vein treatment	Polidocanol, sodium tetradecyl sulfate	Vascular surgeons, phlebologists, outpatient centers	Reimbursement and guideline-driven
Foam sclerotherapy	Polidocanol foam and physician-prepared foam	Vein specialists and hospitals	Higher technology and training component
Vascular malformations	Ethanol, polidocanol, sodium tetradecyl sulfate	Interventional radiology and pediatric vascular teams	Lower volume, higher procedural complexity
Esophageal varices	Ethanolamine oleate and other agents	Hospitals and gastroenterology units	Geographic variation in product use and approval
Hemorrhoidal sclerotherapy	Ethanolamine oleate and related agents	Gastroenterology and colorectal practices	Regional and indication-specific demand

Drug revenue is generally small compared with the revenue generated by the associated procedure, imaging, facility use, and physician services. This limits the willingness of manufacturers to invest in expensive standalone formulation patents for conventional liquid products.

What patents protect sclerosing solutions?

Core composition patents for the leading liquid sclerosants have largely expired or have limited practical relevance. The commercially important patent activity is concentrated in delivery and formulation technology.

Core active ingredients

Polidocanol, also known as lauromacrogol 400, is a long-established nonionic surfactant. Sodium tetradecyl sulfate is also an established small-molecule surfactant sclerosant. Ethanolamine oleate and sodium morrhuate are legacy agents. Their age and broad prior-art history reduce the likelihood that a new patent can validly cover the active ingredient itself.

Patent claims in this area are more likely to cover:

• Concentration ranges with defined tolerability or efficacy characteristics.
• Specific pH, osmolality, purity, or impurity profiles.
• Stabilized compositions.
• Pre-filled syringes or ready-to-use containers.
• Foam-generating systems.
• Gas-to-liquid ratios and bubble-size distributions.
• Catheter delivery and image-guided administration.
• Combination treatment with ultrasound, laser, or other vascular interventions.
• Manufacturing controls for sterile injectable products.

Formulation and foam patents

Foam sclerotherapy creates the most commercially relevant patent layer. Patentable variables include:

• The sclerosant concentration.
• The gas composition, including air, carbon dioxide, nitrogen, or mixtures.
• The liquid-to-gas ratio.
• Bubble size and persistence.
• Surfactant concentration.
• Mixing method and device geometry.
• Syringe, valve, connector, and transfer components.
• Shelf-life and storage conditions.
• Delivery through a catheter or needle under ultrasound guidance.

Varithena is the most visible U.S. example of a proprietary foam product. The product uses polidocanol and a proprietary low-nitrogen gas formulation. Its intellectual-property position is therefore materially different from that of conventional liquid polidocanol or sodium tetradecyl sulfate.

What is the Orange Book status of polidocanol and sodium tetradecyl sulfate?

FDA-approved sclerosing products are evaluated through product-specific labeling, manufacturing, and safety requirements. Orange Book protection is narrower than the broader patent universe because only patents submitted for approved drug products and accepted for listing appear there.

Product	Active ingredient	FDA approval	Orange Book relevance
Asclera	Polidocanol	2010	Product-specific approval; patent status must be checked against current FDA listings
Varithena	Polidocanol foam	2013	Proprietary foam product with formulation and delivery differentiation
Sotradecol	Sodium tetradecyl sulfate	Legacy FDA-approved product	Generic and abbreviated-application competition is structurally possible

An Orange Book listing does not establish that every patent covering a product has been listed. Device patents, process patents, foreign patents, and patents that do not meet FDA listing requirements can remain outside the Orange Book.

When do sclerosing solutions lose exclusivity?

The conventional liquid market has already lost most composition-based exclusivity. Market entry is therefore governed by regulatory approval, sterile manufacturing capability, supply reliability, and clinician adoption.

Exclusivity timeline

Product or technology	Exclusivity driver	Market timing
Conventional polidocanol solution	Active ingredient and formulation history	Mature and largely off-patent
Conventional sodium tetradecyl sulfate	Legacy composition and generic competition	Mature and largely off-patent
Ethanolamine oleate	Long-established active ingredient	Mature; availability varies by jurisdiction
Proprietary polidocanol foam	Product-specific approval and formulation system	More protected than liquid sclerosants
Foam-generation devices	Device and process patents	Rights depend on jurisdiction and claim scope
Image-guided delivery methods	Method-of-use and device claims	Fragmented; often vulnerable to design-around

The main commercial distinction is between freedom to use an old active ingredient and the ability to market a particular FDA-approved product. A manufacturer may have freedom to develop a liquid generic while still facing regulatory or patent barriers associated with a proprietary foam product.

Which companies are challenging or competing with branded sclerosants?

The competitive field includes branded manufacturers, generic injectable companies, specialty compounding pharmacies, and medical-device developers.

Competitive groups

Branded pharmaceutical companies. These companies compete through FDA-approved labeling, physician familiarity, manufacturing controls, and distribution. Merit Medical is associated with Sotradecol. BTG, later acquired by Boston Scientific, developed Varithena.

Generic injectable manufacturers. Generic competition can focus on sodium tetradecyl sulfate or liquid polidocanol where an approved reference product and viable abbreviated pathway exist.

Compounding pharmacies. Compounded sclerosants may be used when commercial supply is limited or when a clinician requires a specific concentration or presentation. Compounding creates price competition but does not confer the same regulatory status as an FDA-approved product.

Device companies. Device manufacturers compete in foam preparation, catheter delivery, ultrasound guidance, and automated administration. Device innovation can capture value even when the drug itself is generic.

What patent litigation affects sclerosing solutions?

Sclerosing-solution litigation is less prominent than litigation involving oncology, immunology, or diabetes products. The lower drug revenue base reduces the incentive to bring large-scale Hatch-Waxman litigation.

The most likely disputes involve:

• Paragraph IV certifications against patents listed for proprietary foam products.
• Patent infringement involving foam preparation or gas-mixing devices.
• Trade-secret claims involving sterile manufacturing or gas formulations.
• Trademark disputes over product names.
• Regulatory disputes involving compounded products.
• Patent challenges to method-of-use claims for vascular malformations or varicose veins.

Paragraph IV risk

A generic applicant challenging a listed patent may file a Paragraph IV certification. The reference-product holder can then bring an infringement action under the Hatch-Waxman framework, potentially triggering a 30-month stay of approval under the applicable statutory conditions.

For conventional liquid products, Paragraph IV risk is likely to be limited by the age of the technology and the absence of commercially important blocking composition patents. For proprietary foam products, risk is higher because patents may cover the product's gas composition, foam properties, container system, or administration method.

How strong is the patent estate for sclerosing solutions?

Conventional liquid sclerosants: weak to moderate

The patent estate for liquid polidocanol and sodium tetradecyl sulfate is generally weak for core composition claims. The principal barriers are regulatory rather than patent-based:

• Sterile injectable manufacturing.
• Demonstration of pharmaceutical equivalence.
• Stability and impurity control.
• Container-closure compatibility.
• Pharmacovigilance and labeling.
• Reliable supply of pharmaceutical-grade active ingredient.

Proprietary foam products: moderate

Foam products have stronger protection because they combine an established active ingredient with a controlled delivery platform. Patent strength depends on whether claims cover the essential commercial attributes or merely narrow implementation details.

Strong claims generally cover:

• Defined foam composition and gas content.
• Critical bubble-size or persistence parameters.
• Integrated preparation and delivery systems.
• Product-specific stability characteristics.
• Clinical use linked to a particular formulation.

Weaker claims generally cover:

• Broad use of polidocanol for vein treatment.
• Generic foam preparation steps.
• Conventional syringes and connectors.
• Treatment methods already described in clinical literature.

What manufacturing and intellectual-property barriers exist?

Manufacturing is a more significant barrier than molecule-level patent protection.

Manufacturing barriers

Sterile sclerosants require validated aseptic processing or terminal sterilization compatible with the formulation. Key technical issues include:

• Control of endotoxins and particulate matter.
• Consistent concentration of surfactant.
• Extractables and leachables from syringes and vials.
• Stability under refrigerated and room-temperature conditions.
• Control of foam gas composition.
• Reproducible bubble-size distribution.
• Compatibility with needles, catheters, and injection pressure.

Foam products add specialized controls that can increase development cost and create technical differentiation. These controls can support process patents even when the underlying active ingredient is old.

What generic launch scenarios exist?

Scenario	Commercial effect	Patent risk
Generic liquid sodium tetradecyl sulfate	Price erosion and broader clinic access	Low to moderate
Generic liquid polidocanol	Pressure on branded liquid products	Low to moderate
Authorized generic	Rapid price competition without independent development risk	Low
Compounded liquid product	Localized price and supply competition	Regulatory and quality risk
Generic or competing polidocanol foam	Larger impact on proprietary foam franchise	Moderate to high
Competing foam device	May reduce device-related exclusivity without replacing the drug	Depends on claims
New sclerosant formulation	Potential premium pricing	Requires clinical and regulatory differentiation

A generic liquid launch would likely affect drug acquisition cost more than total procedure economics. A competing foam product could have a larger commercial effect because it would challenge both the drug product and the associated procedural workflow.

What biosimilar risk exists for sclerosing solutions?

Biosimilar risk is effectively absent. Sclerosing solutions are small-molecule chemical drugs, not biologics. The relevant competitive pathways are abbreviated new drug applications, hybrid applications in some jurisdictions, 505(b)(2) applications, and device or combination-product pathways.

A 505(b)(2) strategy could be relevant for:

• A new concentration.
• A new foam presentation.
• A new route or delivery system.
• A new indication.
• A proprietary container or pre-filled syringe.
• A reformulated product with clinical or safety differentiation.

How does the sclerosing-solutions market compare with competing vascular therapies?

Sclerotherapy competes with endovenous thermal ablation, cyanoacrylate closure, mechanochemical ablation, surgery, and conservative management.

Therapy	Main advantage	Main limitation	IP profile
Liquid sclerotherapy	Low drug cost and broad office use	Multiple sessions may be required	Limited core-drug protection
Foam sclerotherapy	Better contact with larger veins	Requires preparation and training	Stronger formulation and device protection
Thermal ablation	Durable treatment for selected veins	Equipment and anesthesia requirements	Device-heavy patent landscape
Cyanoacrylate closure	Nonthermal, non-tumescent approach	Higher product cost	Product and delivery-system patents
Mechanochemical ablation	Reduced thermal injury	Specialized catheter	Device and method patents
Surgical stripping	Established clinical approach	Invasive and resource-intensive	Limited drug relevance

The main growth opportunity for sclerosing solutions is in office-based treatment, smaller venous segments, recurrent disease, and lesions unsuitable for thermal procedures. The main competitive pressure comes from device-based interventions with stronger proprietary platforms.

What licensing deals affect the sector?

Licensing activity is more likely to involve formulation technology, delivery devices, regional commercialization rights, and manufacturing arrangements than rights to the underlying sclerosant.

Relevant deal structures include:

• Regional rights to polidocanol or sodium tetradecyl sulfate.
• Licensing of foam-generation technology.
• Contract manufacturing and supply agreements.
• Distribution rights for specialty injectables.
• Co-development of catheter or imaging systems.
• Acquisition of a product line with established regulatory approvals.

The acquisition of BTG by Boston Scientific transferred Varithena into a larger interventional-medicine portfolio. The transaction illustrates the strategic value of proprietary vascular products and procedure integration, even where the active ingredient itself is not novel.

What is the geographic coverage of sclerosing-solution patents?

Patent protection is jurisdiction-specific. A product may have meaningful protection in the United States while facing generic competition in Europe, Japan, or emerging markets.

Key geographic differences include:

• U.S. Orange Book listing and Hatch-Waxman litigation.
• European patent validation and national revocation actions.
• Canadian and Australian abbreviated regulatory pathways.
• Regional differences in approval of ethanolamine oleate and sodium morrhuate.
• Greater reliance on physician compounding in markets with limited commercial supply.
• Different treatment of device patents and method-of-use claims.

For multinational diligence, the patent family must be reviewed separately by jurisdiction. A U.S. patent expiration date does not establish freedom to launch globally.

Key Takeaways

• Sclerosing solutions are a mature, generic-heavy drug category.
• Polidocanol and sodium tetradecyl sulfate are the principal FDA-relevant commercial agents.
• Core active-ingredient patents provide limited current protection.
• Proprietary foam formulations, gas systems, delivery devices, and manufacturing methods carry the main patent value.
• Paragraph IV litigation risk is lower for conventional liquid products and higher for proprietary foam products.
• Biosimilar competition does not apply because these are small-molecule drugs.
• Manufacturing quality, sterile supply, regulatory approval, and clinician adoption are stronger barriers than molecule-level patents.
• Procedure economics favor low-cost liquid sclerosants, while proprietary foam products can support higher margins.
• Geographic freedom to launch requires separate review of U.S., European, and other national rights.
• The most credible generic launch scenario is a liquid product; the most commercially disruptive scenario is a competing foam product.

FAQs

Is polidocanol still patent protected?

The active ingredient is an established compound with limited practical composition-patent protection. Current commercial protection is more likely to arise from proprietary foam formulations, delivery systems, manufacturing processes, or product-specific regulatory rights.

Is sodium tetradecyl sulfate a generic drug?

Sodium tetradecyl sulfate is an established injectable sclerosant with a mature competitive profile. Product-specific FDA approval, manufacturing compliance, and reference-product requirements still apply to any generic entrant.

Can a compounded sclerosant compete with an FDA-approved product?

A compounded product may compete on price or availability, but it does not have the same regulatory status, labeling framework, or manufacturing controls as an FDA-approved product.

Does Varithena compete directly with liquid polidocanol?

Yes. Both contain polidocanol and treat venous disease, but Varithena is a proprietary foam product with different preparation, delivery, and clinical-use characteristics.

Are sclerosing solutions subject to biosimilar approval?

No. These products are chemical small molecules. Competition proceeds through generic, hybrid, or reformulation pathways rather than the biosimilar framework.

References

1. National Library of Medicine. (n.d.). Sclerosing solutions. Medical Subject Headings. https://www.ncbi.nlm.nih.gov/mesh
2. U.S. Food and Drug Administration. (2010). Asclera (polidocanol) injection prescribing information.
3. U.S. Food and Drug Administration. (2013). Varithena (polidocanol injectable foam) prescribing information.
4. U.S. Food and Drug Administration. (n.d.). Sotradecol (sodium tetradecyl sulfate injection) prescribing information.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
6. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV certifications.
7. Boston Scientific Corporation. (2019). Annual report.
8. European Medicines Agency. (n.d.). Lauromacrogol 400 and sclerotherapy-related regulatory information.